An Antidote to Long-Standing Care and Cost Outcomes Analysis Frustrations Life Sciences Download

PurpleLab’s® Provider Data is the foundation of our simple to use provider data analytics solutions. This single source of truth provides healthcare organizations with the most comprehensive and up to date provider information Life Sciences Download Let’s Talk! Previous Next

The research is clear: Data drives better health outcomes.  Data has the power to transform how healthcare is delivered and guide organizations toward more patient-centered, value-driven care. Even though data is abundant, it’s often siloed or delivered in disparate data sets, and companies commonly lack the necessary resources to turn the data into insights.   Making…

PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data This video was created in collaboration with the Applied Clinical Trials. Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates. Learn More About: Utilizing…

This study was run to determine if a racial disparity exists in biomarker testing for NSCLC (non-small cell lung cancer) patients. Jared Safran, PharmD, MS, Russell Robbins, MD, MBA, Maggie Mendes, Douglas Londono, PhD, Grace Kane, MS. Healthcare is evolving into precision medicine or what the FDA refers to as personalized medicine1. This targeted approach…

PurpleLab’s® Clinical Trial data provides detailed metrics on clinical trial activities performed by healthcare providers (HCPs) and healthcare organizations (HCOs). By integrating clinical trial data, overall profiles of HCPs and HCOs are enhanced, offering a clearer view of a provider’s clinical research experience. With this added visibility, users can efficiently segment and identify potential investigators and…

This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD). Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.  The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar…

Study is to assess the SARS-CoV-2 antibody levels over time (2021-2022), measured with the Elecsys Anti-SARS-COV-2 S assay, in the real-world setting, and assess the association between them and subsequent COVID-19 outcomes. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon presented a poster during ISPE 2024. The objective of this…

PurpleLab® goes further than raw claims data, by serving longitudinal patient data in combination with our no-code HealthNexus platform, to deliver on-demand insights, in minutes. HealthNexus, harmonizes the complex intersections created by the array of disparate healthcare vocabularies that annotate the factual account of a patient’s journey along with the reporting dimensions of critical need….